Hepatotoxicity in patients prescribed efavirenz or Nevirapine

European Journal of Medical Research

Volumn 13, Issue 7, 2008, Pages 343-348

  Brück, Sandra ^a,d   Witte, S ^a   Brust, J ^b   Schuster, D ^b   Mosthaf, E ^b   Procaccianti, M ^b   Rump, J A ^b   Klinker, H ^c   Petzold, D ^a   Hartmann, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b University of Würzburg ^*

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Efavirenz; Hepatotoxicity; HIV; LEE; Nevirapine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; NEVIRAPINE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GERMANY; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PATIENT SELECTION; PRESCRIPTION; RATING SCALE; RISK FACTOR; SIDE EFFECT; VIRUS DETECTION;

EID: 49749098481     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD and the HIV Outpatient Study Investigators (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853-860.
2. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J (1998). Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351: 543-9.
3. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon RJ, Mallal SA (2001). Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15: 795-797.
4. Walker UA, Setzer B, Venhoff N (2002). Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transciptase inhibitors. AIDS 16: 2165-2173.
5. Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB (2003). Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systematic review. Clin Infect Dis 37: 959-972.
6. den Brinker M, Wit FNM, Wertheim-van Dillen PME, Jurriaans S, Wed J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Jan Weverling G, Lange JMA (2000). Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14: 2895-2902.
7. Sulkowsky MS, Thomas DL, Chaisson RE, Moore RD (2000). Hepatotoxicity associated with antiretroviral therapy in adults infected with Human Immunodeficiency Virus and the role of hepatitis C or B virus infection. J Am Med Ass 283: 74-80.
8. Wit FWN, Weverling GJ, Weel J, Jurriaans S, Lange JMA (2002). Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 186: 23-31.
9. Monforte Ad'A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, Vigevani GM, Tirelli U, Bruno R, Gritti F, Piazza M, Chigiotti S, Chirianni A, De Stefano C, Pizzigallo E, Perretla O, Moroni M (2001). Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquit Immune Defic Syndr 28: 114-123.
10. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V (2001). Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquit Immune Defic Syndr 27: 426-431.
11. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G for the HIV-HCV Co-Infection Study Group (2003). Severe hepatotoxicity during combination anti-retroviral treatment: Incidence, liver histology, and outcome. J Acquit Immune Defic Syndr 32: 259-267.
12. Powderly B (2004). The tolerability profile of nevirapine - short and long term. Boehringer Ingelheim International, Spring Symposium 2004, Rhodes, Greece.
13. Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001 15: 1261-1268.
14. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, Cadrobbi P (1999). Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 29: 455-456.
15. de Maat MMR, ter Heine R, van Gorp ECM, Mulder JW, Mairuhu ATA, Beijnen JH (2003). Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 17: 2209-2214.
16. Gökengin D, Yamazhan T (2002). Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report. Ann Clin Microbiol Antimicrob 1: 1-3.
17. González de Requena G, Núnez M, Jiménez-Nácher I, Soriano V (2002). Liver toxicity caused by nevirapine. AIDS 16: 290-291.
18. Piliero PJ, Purdy B (2001). Nevirapine-induced hepatitis: A case series and review of literature. AIDS Read 11: 379-382.
19. Prakash M, Poreddy V, Tiyyagura L, Bonacini M (2001). Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol 96: 1571-1574.
20. Palmon R, Koo BCA, Shoultz DA, Dieterich DT (2002). Lack of hepatotoxicity associated with Nonnucleoside reverse transciptase inhibitors. J Acquir Immune Defic Syndr 29: 340-345.
21. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JMA; Phanuphak P, Cooper DA (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17: 2191-2199.
22. Sulkowsky MS, Thomas DL, Chaisson RE, Moore RD (2000). Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. J Am Med Ass 283: 74-80.
23. Sulkowsky MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (2002). Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 35: 182-189.
24. Martin-Carbanero L, Nunez M, Rios P, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V (2002). Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 16: 1423-1423.
25. Van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group (2003). Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 17: 2227-2236.
26. Viramune® product information (2004), Boehringer Ingelhelm.
27. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D (2000). The natural history of hepatitis C virus infection: host, viral, and environmental factors. J Am Med Ass 284: 430-456.